Boehringer Ingelheim has acquired University of Basel spinout T3 Pharmaceuticals for 450 million CHF ($507.4 million) in an effort to expand its immuno-oncology portfolio with T3’s platform. The …
Read Full Story at source (may require registration)
Latest posts by Business Editor (see all)
- What is Meant by “Discovery” in Sales? A Strategy for Building Trust and Driving Conversions - March 12, 2025
- How to Sell a Small Business: A Starter Guide for Business Owners - February 3, 2025
- European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024
